Research programme: atrial natriuretic factor peptides - BTG/Genentech
Latest Information Update: 21 Aug 2019
Price :
$50 *
At a glance
- Originator Genentech
- Developer BTG
- Class
- Mechanism of Action Atrial peptide agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure; Renal failure; Renal hypertension
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 23 Feb 2006 No development reported - Preclinical for Congestive heart failure in United Kingdom (unspecified route)
- 23 Feb 2006 No development reported - Preclinical for Renal failure in United Kingdom (unspecified route)